IMGN 779

Drug Profile

IMGN 779

Alternative Names: IMGN779

Latest Information Update: 10 Jul 2017

Price : $50

At a glance

  • Originator ImmunoGen
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Alkylating agents; CD33 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia
  • Research Myelodysplastic syndromes

Most Recent Events

  • 26 Jun 2017 Adverse events, pharmacokinetics, and pharmacodynamics data from a phase I trial in Acute myeloid leukaemia released by ImmunoGen
  • 03 Dec 2016 Pharmacodynamics data from a preclinical study in Acute myeloid leukaemia (Combination therapy) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-2016)
  • 01 Mar 2016 Phase-I clinical trials in Acute myeloid leukaemia (Monotherapy, Second-line therapy or greater) in USA (IV) (NCT02674763)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top